Suven Life Sciences secures three (3) Product Patents

In Canada, ARIPO and South Korea

Suven Life Sciences announced the grant of one (1) product patent from Canada (2823548), one (1) product patent from ARIPO (AP 3307) and one (1) product patent from South Korea (10-1551481) corresponding to the New Chemical Entities (NCEs) for the treatment of disorders associated with Neurodegenerative diseases and these Patents are valid through 2030.

The granted claims of the patents include the class of selective 5-HT compounds discovered by Suven and are being developed as therapeutic agents and are useful in the treatment of cognitive impairment associated with neurodegenerative disorders like Alzheimer's disease, Attention deficient hyperactivity disorder (ADHD), Huntington's disease, Parkinson and Schizophrenia.

 

Powered by Capital Market - Live News